1Kroger LA, Denardo GL, Gumerlock PH, et al. Apoptosis related gene and protein expression in human lymphoma xenografts (Raji) after low dose rate radiation using ^67Cu-2IT-BAT-Lym-I radioimmunotherapy[J]. Cancer Biother Radiopharrn,2001,16:213-225.
2Knox SJ, Goris ML,Trisler ,et al. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma[J]. Clin Cancer Res, 1996,12:457-470.
3Gestin JF, Loussouarn A, Bardies M, et al. Two -step targeting of xenografted colon carcinoma using a bispecific antibody and 188Re-labeled bivalent hapten:biodistribution and dosimetry studies[J]. J Nucl Med, 2001,42 : 146-153.
4Zinzani PL, Tani M, Pulsoni A,et al. Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial:A phase II non- randomised trial (FLUMIZ)[J]. Lancet Oncol,2008,9(4) :352-358.
5Liersch T, Meller J, Bittrich M,et al. Update of carcinoembryonic antigen radio immunotherapy with (131)I-labetuzumab after salvage resection of colorectal liver metastases : Comparison of outcome to a contemporaneous control group[J].Ann Surg Oncol, 2007,14 (9) : 2577- 2590.
7Buckman R, DeAngelis C, Shaw P, et al. Intraperitoneal therapy of malignant aseites associated with carcinoma of ovary and breast using radioiodinated monoelonal antibody 2G3 [J]. Gyneeol Oncol, 1992,47 (1) : 102-109.
